Your browser doesn't support javascript.
Cross-Sectional Exploration of Plasma Biomarkers of Alzheimer's Disease in Down Syndrome: Early Data from the Longitudinal Investigation for Enhancing Down Syndrome Research (LIFE-DSR) Study.
Hendrix, James A; Airey, David C; Britton, Angela; Burke, Anna D; Capone, George T; Chavez, Ronelyn; Chen, Jacqueline; Chicoine, Brian; Costa, Alberto C S; Dage, Jeffrey L; Doran, Eric; Esbensen, Anna; Evans, Casey L; Faber, Kelley M; Foroud, Tatiana M; Hart, Sarah; Haugen, Kelsey; Head, Elizabeth; Hendrix, Suzanne; Hillerstrom, Hampus; Kishnani, Priya S; Krell, Kavita; Ledesma, Duvia Lara; Lai, Florence; Lott, Ira; Ochoa-Lubinoff, Cesar; Mason, Jennifer; Nicodemus-Johnson, Jessie; Proctor, Nicholas Kyle; Pulsifer, Margaret B; Revta, Carolyn; Rosas, H Diana; Rosser, Tracie C; Santoro, Stephanie; Schafer, Kim; Scheidemantel, Thomas; Schmitt, Frederick; Skotko, Brian G; Stasko, Melissa R; Talboy, Amy; Torres, Amy; Wilmes, Kristi; Woodward, Jason; Zimmer, Jennifer A; Feldman, Howard H; Mobley, William.
  • Hendrix JA; LuMind IDSC, 20 Mall Road, Suite 200, Burlington, MA 01803-4126, USA.
  • Airey DC; Eli Lilly and Company, 893 Delaware St. Indianapolis, IN 46225, USA.
  • Britton A; LuMind IDSC, 20 Mall Road, Suite 200, Burlington, MA 01803-4126, USA.
  • Burke AD; St. Joseph's Hospital and Medical Center, Department of Neurology, Barrow Neurological Institute, 350 W. Thomas Rd., Phoenix, AZ 85013, USA.
  • Capone GT; Down Syndrome Clinic & Research Center, Kennedy Krieger Institute, 707 N. Broadway, Baltimore, MD 21205, USA.
  • Chavez R; Department of Neurosciences, Alzheimer's Disease Cooperative Study, University of California San Diego, 9500 Gilman Dr., La Jolla, CA 92093-0949, USA.
  • Chen J; Rush University Medical Center, Division of Developmental Behavioral Pediatrics, Department of Pediatrics, 1653 W. Congress Pkwy, Chicago, IL 60612, USA.
  • Chicoine B; Adult Down Syndrome Center, Advocate Medical Group, 1610 Luther Lane, Park Ridge, IL 60068, USA.
  • Costa ACS; Division of Neurology and Epilepsy, Department of Pediatrics, Department of Psychiatry, Case Western Reserve University School of Medicine, 10524 Euclid Ave, Cleveland, OH 44106, USA.
  • Dage JL; Eli Lilly and Company, 893 Delaware St. Indianapolis, IN 46225, USA.
  • Doran E; Department of Pediatrics, The University of California, Irvine, 333 The City Blvd. West, Suite 800, Orange, CA 92868-4482, USA.
  • Esbensen A; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH 45229, USA.
  • Evans CL; Division of Developmental and Behavioral Pediatrics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave, Cincinnati, OH 45229, USA.
  • Faber KM; Department of Psychiatry, Massachusetts General Hospital, 55 Fruit St, Boston, MA 02114, USA.
  • Foroud TM; National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD), Indiana University School of Medicine, 410 W 10th St, Indianapolis, IN 46202, USA.
  • Hart S; National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD), Indiana University School of Medicine, 410 W 10th St, Indianapolis, IN 46202, USA.
  • Haugen K; Duke University Medical Center, Department of Pediatrics, 2301 Erwin Road, Durham, NC 27705, USA.
  • Head E; Down Syndrome Program, Division of Medical Genetics and Metabolism, Department of Pediatrics, Massachusetts General Hospital, 55 Fruit St, Boston, MA 02114, USA.
  • Hendrix S; Department of Pathology and Laboratory Medicine, The University of California, Irvine, School of Medicine, 1111 Gillepsie Neuroscience Research Facility, Irvine, CA 92697, USA.
  • Hillerstrom H; Pentara Corporation, 2261 East 3300 South, Suite 200, Millcreek, UT 84109, USA.
  • Kishnani PS; LuMind IDSC, 20 Mall Road, Suite 200, Burlington, MA 01803-4126, USA.
  • Krell K; Duke University Medical Center, Department of Pediatrics, 2301 Erwin Road, Durham, NC 27705, USA.
  • Ledesma DL; Down Syndrome Program, Division of Medical Genetics and Metabolism, Department of Pediatrics, Massachusetts General Hospital, 55 Fruit St, Boston, MA 02114, USA.
  • Lai F; Department of Neurosciences, Alzheimer's Disease Cooperative Study, University of California San Diego, 9500 Gilman Dr., La Jolla, CA 92093-0949, USA.
  • Lott I; Department of Neurology, Massachusetts General Hospital, McLean Hospital, and Harvard Medical School, 55 Fruit St, Boston, MA 02114, USA.
  • Ochoa-Lubinoff C; Department of Pediatrics, The University of California, Irvine, 333 The City Blvd. West, Suite 800, Orange, CA 92868-4482, USA.
  • Mason J; Rush University Medical Center, Division of Developmental Behavioral Pediatrics, Department of Pediatrics, 1653 W. Congress Pkwy, Chicago, IL 60612, USA.
  • Nicodemus-Johnson J; Department of Neurosciences, Alzheimer's Disease Cooperative Study, University of California San Diego, 9500 Gilman Dr., La Jolla, CA 92093-0949, USA.
  • Proctor NK; Pentara Corporation, 2261 East 3300 South, Suite 200, Millcreek, UT 84109, USA.
  • Pulsifer MB; Eli Lilly and Company, 893 Delaware St. Indianapolis, IN 46225, USA.
  • Revta C; Department of Psychiatry, Massachusetts General Hospital, 55 Fruit St, Boston, MA 02114, USA.
  • Rosas HD; Department of Neurosciences, Alzheimer's Disease Cooperative Study, University of California San Diego, 9500 Gilman Dr., La Jolla, CA 92093-0949, USA.
  • Rosser TC; Department of Neurology, Massachusetts General Hospital, McLean Hospital, and Harvard Medical School, 55 Fruit St, Boston, MA 02114, USA.
  • Santoro S; Department of Human Genetics, Emory University, 615 Michael Street, Suite 301, Atlanta, GA 30322, USA.
  • Schafer K; Down Syndrome Program, Division of Medical Genetics and Metabolism, Department of Pediatrics, Massachusetts General Hospital, 55 Fruit St, Boston, MA 02114, USA.
  • Scheidemantel T; Department of Pediatrics, Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA.
  • Schmitt F; Department of Neurosciences, Alzheimer's Disease Cooperative Study, University of California San Diego, 9500 Gilman Dr., La Jolla, CA 92093-0949, USA.
  • Skotko BG; University Hospitals Cleveland Medical Center, Department of Psychiatry, Case Western Reserve University School of Medicine, 10524 Euclid Ave, Cleveland, OH 44106, USA.
  • Stasko MR; Sanders-Brown Center on Aging, University of Kentucky, 800 S. Limestone St., Lexington, KY 40536, USA.
  • Talboy A; Down Syndrome Program, Division of Medical Genetics and Metabolism, Department of Pediatrics, Massachusetts General Hospital, 55 Fruit St, Boston, MA 02114, USA.
  • Torres A; Department of Pediatrics, Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA.
  • Wilmes K; University Hospitals Cleveland Medical Center, Department of Psychiatry, Case Western Reserve University School of Medicine, 10524 Euclid Ave, Cleveland, OH 44106, USA.
  • Woodward J; Department of Human Genetics, Emory University School of Medicine, 1365 Clifton Road, NE, Building A, Suite 2200, Atlanta, GA 30322, USA.
  • Zimmer JA; Down Syndrome Program, Division of Medical Genetics and Metabolism, Department of Pediatrics, Massachusetts General Hospital, 55 Fruit St, Boston, MA 02114, USA.
  • Feldman HH; National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD), Indiana University School of Medicine, 410 W 10th St, Indianapolis, IN 46202, USA.
  • Mobley W; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH 45229, USA.
J Clin Med ; 10(9)2021 Apr 28.
Article in English | MEDLINE | ID: covidwho-1238901
ABSTRACT
With improved healthcare, the Down syndrome (DS) population is both growing and aging rapidly. However, with longevity comes a very high risk of Alzheimer's disease (AD). The LIFE-DSR study (NCT04149197) is a longitudinal natural history study recruiting 270 adults with DS over the age of 25. The study is designed to characterize trajectories of change in DS-associated AD (DS-AD). The current study reports its cross-sectional analysis of the first 90 subjects enrolled. Plasma biomarkers phosphorylated tau protein (p-tau), neurofilament light chain (NfL), amyloid ß peptides (Aß1-40, Aß1-42), and glial fibrillary acidic protein (GFAP) were undertaken with previously published methods. The clinical data from the baseline visit include demographics as well as the cognitive measures under the Severe Impairment Battery (SIB) and Down Syndrome Mental Status Examination (DS-MSE). Biomarker distributions are described with strong statistical associations observed with participant age. The biomarker data contributes to understanding DS-AD across the spectrum of disease. Collectively, the biomarker data show evidence of DS-AD progression beginning at approximately 40 years of age. Exploring these data across the full LIFE-DSR longitudinal study population will be an important resource in understanding the onset, progression, and clinical profiles of DS-AD pathophysiology.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Observational study / Prognostic study / Randomized controlled trials Language: English Year: 2021 Document Type: Article Affiliation country: Jcm10091907

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Observational study / Prognostic study / Randomized controlled trials Language: English Year: 2021 Document Type: Article Affiliation country: Jcm10091907